FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2186473865> ?p ?o ?g. }

• W2186473865 endingPage "1690" @default.
• W2186473865 startingPage "1684" @default.
• W2186473865 abstract "Calcineurin inhibitors (CNIs) reduce short-term kidney transplant failure, but might contribute to transplant failure in the long-term. The role of alemtuzumab (a potent lymphocyte-depleting antibody) as an induction treatment followed by an early reduction in CNI and mycophenolate exposure and steroid avoidance, after kidney transplantation is uncertain. We aimed to assess the efficacy and safety of alemtuzumab-based induction treatment compared with basiliximab-based induction treatment in patients receiving kidney transplants.For this randomised trial, we enrolled patients aged 18 years and older who were scheduled to receive a kidney transplant in the next 24 h from 18 transplant centres in the UK. Using minimised randomisation, we randomly assigned patients (1:1; minimised for age, sex, and immunological risk) to either alemtuzumab-based induction treatment (ie, alemtuzumab followed by low-dose tacrolimus and mycophenolate without steroids) or basiliximab-based induction treatment (basiliximab followed by standard-dose tacrolimus, mycophenolate, and prednisolone). Participants were reviewed at discharge from hospital and at 1, 3, 6, 9, and 12 months after transplantation. The primary outcome was biopsy-proven acute rejection at 6 months, analysed by intention to treat. The study is registered at ClinicalTrials.gov, number NCT01120028, and isrctn.org, number ISRCTN88894088.Between Oct 4, 2010, and Jan 21, 2013, we randomly assigned 852 participants to treatment: 426 to alemtuzumab-based treatment and 426 to basiliximab-based treatment. Overall, individuals allocated to alemtuzumab-based treatment had a 58% proportional reduction in biopsy-proven acute rejection compared with those allocated to basiliximab-based treatment (31 [7%] patients in the alemtuzumab group vs 68 [16%] patients in the basiliximab group; hazard ratio (HR) 0·42, 95% CI 0·28-0·64; log-rank p<0·0001). We detected no between-group difference in treatment effect on transplant failure during the first 6 months (16 [4%] patients vs 13 [3%] patients; HR 1·23, 0·59-2·55; p=0·58) or serious infection (135 [32%] patients vs 136 [32%] patients; HR 1·02, 0·80-1·29; p=0·88). During the first 6 months after transplantation, 11 (3%) patients given alemtuzumab-based treatment and six (1%) patients given basiliximab-based treatment died (HR 1·79, 95% CI 0·66-4·83; p=0·25).Compared with standard basiliximab-based treatment, alemtuzumab-based induction therapy followed by reduced CNI and mycophenolate exposure and steroid avoidance reduced the risk of biopsy-proven acute rejection in a broad range of patients receiving a kidney transplant. Long-term follow-up of this trial will assess whether these effects translate into differences in long-term transplant function and survival.UK National Health Service Blood and Transplant Research and Development Programme, Pfizer, and Novartis UK." @default.
• W2186473865 created "2016-06-24" @default.
• W2186473865 creator A5002816008 @default.
• W2186473865 creator A5030243760 @default.
• W2186473865 creator A5030250235 @default.
• W2186473865 creator A5043842591 @default.
• W2186473865 creator A5055986570 @default.
• W2186473865 creator A5065348937 @default.
• W2186473865 creator A5079926383 @default.
• W2186473865 creator A5088900128 @default.
• W2186473865 date "2014-11-01" @default.
• W2186473865 modified "2023-09-26" @default.
• W2186473865 title "Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial" @default.
• W2186473865 cites W1598428215 @default.
• W2186473865 cites W1737600104 @default.
• W2186473865 cites W1976649705 @default.
• W2186473865 cites W2000366267 @default.
• W2186473865 cites W2006146908 @default.
• W2186473865 cites W2013256551 @default.
• W2186473865 cites W2024754526 @default.
• W2186473865 cites W2026399893 @default.
• W2186473865 cites W2038252730 @default.
• W2186473865 cites W2066871841 @default.
• W2186473865 cites W2070761004 @default.
• W2186473865 cites W2076418965 @default.
• W2186473865 cites W2098974363 @default.
• W2186473865 cites W2104170524 @default.
• W2186473865 cites W2127536951 @default.
• W2186473865 cites W2150045477 @default.
• W2186473865 cites W2333006548 @default.
• W2186473865 cites W3147894994 @default.
• W2186473865 cites W4214559180 @default.
• W2186473865 cites W4244697632 @default.
• W2186473865 cites W85233391 @default.
• W2186473865 doi "https://doi.org/10.1016/s0140-6736(14)61095-3" @default.
• W2186473865 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25078310" @default.
• W2186473865 hasPublicationYear "2014" @default.
• W2186473865 type Work @default.
• W2186473865 sameAs 2186473865 @default.
• W2186473865 citedByCount "120" @default.
• W2186473865 countsByYear W21864738652014 @default.
• W2186473865 countsByYear W21864738652015 @default.
• W2186473865 countsByYear W21864738652016 @default.
• W2186473865 countsByYear W21864738652017 @default.
• W2186473865 countsByYear W21864738652018 @default.
• W2186473865 countsByYear W21864738652019 @default.
• W2186473865 countsByYear W21864738652020 @default.
• W2186473865 countsByYear W21864738652021 @default.
• W2186473865 countsByYear W21864738652022 @default.
• W2186473865 countsByYear W21864738652023 @default.
• W2186473865 crossrefType "journal-article" @default.
• W2186473865 hasAuthorship W2186473865A5002816008 @default.
• W2186473865 hasAuthorship W2186473865A5030243760 @default.
• W2186473865 hasAuthorship W2186473865A5030250235 @default.
• W2186473865 hasAuthorship W2186473865A5043842591 @default.
• W2186473865 hasAuthorship W2186473865A5055986570 @default.
• W2186473865 hasAuthorship W2186473865A5065348937 @default.
• W2186473865 hasAuthorship W2186473865A5079926383 @default.
• W2186473865 hasAuthorship W2186473865A5088900128 @default.
• W2186473865 hasConcept C126322002 @default.
• W2186473865 hasConcept C126894567 @default.
• W2186473865 hasConcept C128057223 @default.
• W2186473865 hasConcept C141071460 @default.
• W2186473865 hasConcept C168563851 @default.
• W2186473865 hasConcept C2777630719 @default.
• W2186473865 hasConcept C2779015954 @default.
• W2186473865 hasConcept C2780303639 @default.
• W2186473865 hasConcept C2781307858 @default.
• W2186473865 hasConcept C2909675724 @default.
• W2186473865 hasConcept C2911091166 @default.
• W2186473865 hasConcept C71924100 @default.
• W2186473865 hasConceptScore W2186473865C126322002 @default.
• W2186473865 hasConceptScore W2186473865C126894567 @default.
• W2186473865 hasConceptScore W2186473865C128057223 @default.
• W2186473865 hasConceptScore W2186473865C141071460 @default.
• W2186473865 hasConceptScore W2186473865C168563851 @default.
• W2186473865 hasConceptScore W2186473865C2777630719 @default.
• W2186473865 hasConceptScore W2186473865C2779015954 @default.
• W2186473865 hasConceptScore W2186473865C2780303639 @default.
• W2186473865 hasConceptScore W2186473865C2781307858 @default.
• W2186473865 hasConceptScore W2186473865C2909675724 @default.
• W2186473865 hasConceptScore W2186473865C2911091166 @default.
• W2186473865 hasConceptScore W2186473865C71924100 @default.
• W2186473865 hasFunder F4320332756 @default.
• W2186473865 hasIssue "9955" @default.
• W2186473865 hasLocation W21864738651 @default.
• W2186473865 hasLocation W21864738652 @default.
• W2186473865 hasOpenAccess W2186473865 @default.
• W2186473865 hasPrimaryLocation W21864738651 @default.
• W2186473865 hasRelatedWork W1966299088 @default.
• W2186473865 hasRelatedWork W1967915560 @default.
• W2186473865 hasRelatedWork W1983211062 @default.
• W2186473865 hasRelatedWork W2186473865 @default.
• W2186473865 hasRelatedWork W2417597819 @default.
• W2186473865 hasRelatedWork W2586719095 @default.
• W2186473865 hasRelatedWork W2898973131 @default.
• W2186473865 hasRelatedWork W4206820632 @default.
• W2186473865 hasRelatedWork W4235862415 @default.

• next